Literature DB >> 18677113

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Grzegorz M Popowicz, Anna Czarna, Tad A Holak.   

Abstract

The Mdmx oncoprotein has only recently emerged as a critical-independent to Mdm2-regulator of p53 activation. We have determined the crystal structure of the N-terminal domain of human Mdmx bound to a 15-residue transactivation domain peptide of human p53. The structure shows why antagonists of the Mdm2 binding to p53 are ineffective in the Mdmx-p53 interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677113     DOI: 10.4161/cc.6365

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  85 in total

1.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

2.  A stapled p53 helix overcomes HDMX-mediated suppression of p53.

Authors:  Federico Bernal; Mark Wade; Marina Godes; Tina N Davis; David G Whitehead; Andrew L Kung; Geoffrey M Wahl; Loren D Walensky
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 3.  Fine-tuning multiprotein complexes using small molecules.

Authors:  Andrea D Thompson; Amanda Dugan; Jason E Gestwicki; Anna K Mapp
Journal:  ACS Chem Biol       Date:  2012-07-23       Impact factor: 5.100

4.  Identification of a Structural Determinant for Selective Targeting of HDMX.

Authors:  Yael Ben-Nun; Hyuk-Soo Seo; Edward P Harvey; Zachary J Hauseman; Thomas E Wales; Catherine E Newman; Ann M Cathcart; John R Engen; Sirano Dhe-Paganon; Loren D Walensky
Journal:  Structure       Date:  2020-04-30       Impact factor: 5.006

Review 5.  p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Authors:  Howard B Lieberman; Sunil K Panigrahi; Kevin M Hopkins; Li Wang; Constantinos G Broustas
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

6.  Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.

Authors:  Simon M Vogel; Matthias R Bauer; Andreas C Joerger; Rainer Wilcken; Tobias Brandt; Dmitry B Veprintsev; Trevor J Rutherford; Alan R Fersht; Frank M Boeckler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

7.  On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

Authors:  Karim M ElSawy; Chandra S Verma; Thomas L Joseph; David P Lane; Reidun Twarock; Leo S D Caves
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

8.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

10.  Identification and characterization of the first small molecule inhibitor of MDMX.

Authors:  Damon Reed; Ying Shen; Anang A Shelat; Leggy A Arnold; Antonio M Ferreira; Fangyi Zhu; Nicholas Mills; David C Smithson; Catherine A Regni; Donald Bashford; Samantha A Cicero; Brenda A Schulman; Aart G Jochemsen; R Kiplin Guy; Michael A Dyer
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.